# OnCo record lirafugratinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lirafugratinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lirafugratinib" ;
  schema:name "Lirafugratinib"@en ;
  schema:description "An oral FGFR2 inhibitor approved in September 2026 for bile duct cancer whose tumour carries an FGFR2 fusion or rearrangement, after earlier treatment."@en ;
  schema:url <https://onco.cc/drugs/lirafugratinib/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic>, <https://clinicaltrials.gov/search?intr=RLY-4008> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Small-molecule FGFR2 inhibitor" ;
  schema:alternateName "Lyrfigtu" ;
  onco:approval "US 2026: Previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement" ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/> ;
  onco:targets <https://onco.cc/targets/fgfr2/> ;
  onco:companies <https://onco.cc/companies/elevar-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct07359820/> .